News | SPECT Imaging | February 18, 2022

Already used in single-photon emission computed tomography (SPECT) myocardial perfusion imaging (MPI) for adult patients, Rapiscan is now approved for use in stress cardiac magnetic resonance imaging (CMR)

Already used in single-photon emission computed tomography (SPECT) myocardial perfusion imaging (MPI) for adult patients, Rapiscan is now approved for use in stress cardiac magnetic resonance imaging (CMR)

February 18, 2022 — GE Healthcare has announced that it has received approval from the European Medicines Agency (EMA) for additional imaging modalities for its stress agent Rapiscan (Regadenoson). Already an established pharmacological stress agent in SPECT MPI for adult patients, Rapiscan is now approved for use in Magnetic Resonance Imaging (MRI) as well as Computed Tomography (CT) and Positron Emission Tomography (PET).

Rapiscan simulates the effects of exercise in the hearts of adult patients unable to exercise and is used to aid the diagnosis of coronary artery disease (CAD). The approval for additional imaging modalities will enable Rapiscan to be used with an MR contrast agent in stress CMR to assess the function and blood flow of the heart, enabling radiologists/cardiologists to perform a single stress/rest/MRI protocol.

Stress CMR has shown high diagnostic performance (sensitivity and specificity of 90% and above) compared to gold standard invasive imaging for coronary artery disease and is recommended for use in the 2019 European Society of Cardiology guidelines for the diagnosis and management of chronic coronary syndromes, along with other non-invasive diagnostic tests, such as stress SPECT MPI.

Rapiscan can be used across a broad spectrum of patients as it does not require weight and age-based modifications or an infusion pump.

Dr Gianluca Pontone, Director of Cardiovascular Imaging Department, Monzino Cardiology Center at University of Milan said: “Our experience with Rapiscan in stress MR was very positive. We found it easy to use and very effective in helping to speed up the entire examination which was a key factor for us as was the high level of tolerance amongst patients.”

Dr Mark Hibberd, Chief Medical Officer at GE Healthcare Pharmaceutical Diagnostics, said: “Market authorization of the additional imaging modalities for Rapiscan could make it easier for more patients, who are unable to exercise, to have this stress test and aid radiologists and cardiologists in making assessments.”

GE Healthcare has the commercial rights to promote Rapiscan excluding US, Mexico and Canada.

GE Healthcare Pharmaceutical Diagnostics imaging agents support three patient procedures every second worldwide across MRI, X-ray/CT and nuclear medicine imaging. Its portfolio of cardiology products aims to support diagnosis and monitoring throughout the cardiac care pathway and aid treatment decisions across multiple pathologies with products available for use in interventional angiography laboratories, and in CT, MRI, Echocardiography and SPECT imaging.

For more information: www.gehealthcare.com

Related content:

FDA Adds Coronary CT Angiography Indication for GE Healthcare’s Visipaque Contrast Media

Deep Learning with SPECT Accurately Predicts Major Adverse Cardiac Events


Related Content

News | Coronavirus (COVID-19)

March 10, 2023 — Researchers found evidence of heart muscle inflammation in a small number of patients with acute ...

Time March 10, 2023
arrow
News | SPECT-CT

March 2, 2023 —Royal Philips announced new milestones in the development of the world’s first spectral detector angio CT ...

Time March 02, 2023
arrow
News | Computed Tomography (CT)

March 1, 2023 — According to an accepted manuscript published in ARRS’ American Journal of Roentgenology (AJR), using a ...

Time March 01, 2023
arrow
News | PET Imaging

February 23, 2023 — The Society of Nuclear Medicine and Molecular Imaging (SNMMI) and the European Association of ...

Time February 23, 2023
arrow
News | Magnetic Resonance Imaging (MRI)

February 16, 2023 — According to an accepted manuscript published in ARRS’ American Journal of Roentgenology (AJR) ...

Time February 16, 2023
arrow
News | Nuclear Imaging

February 23, 2023 — Editor's note: This news item has been updated to reflect that the FDA has since updated its alert ...

Time February 15, 2023
arrow
News | Prostate Cancer

February 9, 2023 — Blue Earth Diagnostics, a Bracco company and recognized leader in the development and ...

Time February 09, 2023
arrow
News | Digital Radiography (DR)

February 8, 2023 — Carestream Health is partnering with Robarts Research Institute to increase and demonstrate the ...

Time February 08, 2023
arrow
News | Computed Tomography (CT)

January 30, 2023 — Photon-counting detector CT reduces the amount of contrast needed for CT angiography (CTA) while ...

Time January 30, 2023
arrow
News | Radiology Imaging

January 23, 2023 — Canon Medical Systems has released a new eBook featuring its new medical imaging roadshow. This new ...

Time January 23, 2023
arrow
Subscribe Now